DK1294892T3 - Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er) - Google Patents

Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)

Info

Publication number
DK1294892T3
DK1294892T3 DK01946643T DK01946643T DK1294892T3 DK 1294892 T3 DK1294892 T3 DK 1294892T3 DK 01946643 T DK01946643 T DK 01946643T DK 01946643 T DK01946643 T DK 01946643T DK 1294892 T3 DK1294892 T3 DK 1294892T3
Authority
DK
Denmark
Prior art keywords
vlps
influenza virus
particles
wild
aggregation
Prior art date
Application number
DK01946643T
Other languages
English (en)
Inventor
Jose M Galarza
Theresa E Latham
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1294892T3 publication Critical patent/DK1294892T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01946643T 2000-06-23 2001-06-21 Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er) DK1294892T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21365600P 2000-06-23 2000-06-23
US28441101P 2001-04-17 2001-04-17
PCT/US2001/019890 WO2002000885A2 (en) 2000-06-23 2001-06-21 Assembly of wild-type and chimeric influenza virus-like particles (vlps)

Publications (1)

Publication Number Publication Date
DK1294892T3 true DK1294892T3 (da) 2008-01-28

Family

ID=26908276

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01946643T DK1294892T3 (da) 2000-06-23 2001-06-21 Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)

Country Status (17)

Country Link
US (2) US7556940B2 (da)
EP (1) EP1294892B1 (da)
JP (1) JP5008244B2 (da)
KR (1) KR100877019B1 (da)
CN (1) CN1196788C (da)
AT (1) ATE376059T1 (da)
AU (2) AU2001268662A1 (da)
BR (1) BRPI0111830B8 (da)
CA (1) CA2410297C (da)
CY (1) CY1107835T1 (da)
DE (1) DE60130987T2 (da)
DK (1) DK1294892T3 (da)
ES (1) ES2295175T3 (da)
IL (1) IL153290A0 (da)
MX (1) MXPA02012254A (da)
PT (1) PT1294892E (da)
WO (1) WO2002000885A2 (da)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0250488A (ja) * 1988-08-11 1990-02-20 Nec Corp 超伝導配線
KR100877019B1 (ko) * 2000-06-23 2009-01-07 와이어쓰 홀딩스 코포레이션 야생형 및 키메릭 인플루엔자 바이러스성입자(브이엘피)의 조립
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
AU2003251604A1 (en) * 2002-06-26 2004-01-19 F. C. Thomas Allnutt Viruses and virus-like particles for multiple antigen and target display
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
AU2004272972A1 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
AU2011218606B2 (en) * 2003-07-11 2012-01-12 Novavax, Inc Functional influenza virus-like particles (VLPS)
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8551756B2 (en) * 2003-07-11 2013-10-08 Novavax, Inc. Avian influenza chimeric VLPS
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
US20090104226A1 (en) * 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
EP1858332A4 (en) * 2005-02-16 2011-06-22 Lentigen Corp LENTIVIRUS VECTORS AND ITS USE
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
EP1919504B1 (en) 2005-08-03 2013-10-16 iBio, Inc. Antibody to bacillus anthracis protective antigen
BRPI0617486A2 (pt) * 2005-10-18 2011-07-26 Novavax Inc vacina que compreende partÍculas similares a vÍrus da gripe funcionais (vlp) e uso de uma vlp de gripe
JP5603012B2 (ja) * 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
PT1968632E (pt) * 2005-12-06 2012-07-16 Yeda Res & Dev Vacina da gripe melhorada
EP2468296A3 (en) * 2006-02-02 2013-12-04 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
WO2007095320A2 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
AU2007215080A1 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
EP3011969A1 (en) 2006-03-07 2016-04-27 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2007126788A2 (en) * 2006-03-27 2007-11-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the treatment and prevention of viral infection
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US9101578B2 (en) * 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
WO2007130327A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
KR100702034B1 (ko) * 2006-05-12 2007-03-30 삼성전자주식회사 반도체 장치, 이 장치의 전원 노이즈 감소 방법 및 인쇄회로 기판
WO2007144886A2 (en) 2006-06-15 2007-12-21 Ben-Gurion University Of The Negev Research And Development Authority Virus-like particles for treatment of viral infections
RU2009105099A (ru) 2006-07-14 2010-08-27 Санофи Пастер Байолоджикс Ко. (Us) Конструирование рекомбинантных вирусных вакцин путем прямой транспозон-опосредованной инсерции чужеродных иммунологических детерминант в белки векторного вируса
JP2009544322A (ja) * 2006-07-27 2009-12-17 リゴサイト ファーマシューティカルズ インコーポレイテッド キメラウイルス様粒子
AU2007345768B2 (en) * 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
CA2664791A1 (en) * 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co. Recombinant rhinovirus vectors
JP2010508860A (ja) * 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン
EP2679240A1 (en) * 2006-12-06 2014-01-01 Novartis AG Vaccines including antigen from four strains of influenza virus
US7998487B2 (en) * 2007-02-16 2011-08-16 The Salk Institute For Biological Studies Antitoxin and vaccine platform based on nodavirus VLPs
BRPI0810865A2 (pt) * 2007-04-28 2017-05-09 Fraunhofer Usa Inc antígenos de tripanossoma, composições vacinais, e métodos relacionados
US8697088B2 (en) 2007-05-25 2014-04-15 Novavax, Inc. VLPs derived from cells that do not express a viral matrix or core protein
US8404252B2 (en) * 2007-07-11 2013-03-26 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
HUE025149T2 (hu) 2007-08-02 2016-01-28 Biondvax Pharmaceuticals Ltd Multimer multiepitóp influenza vakcinák
CN101820903A (zh) * 2007-08-20 2010-09-01 美国弗劳恩霍夫股份有限公司 预防性和治疗性流感疫苗、抗原、组合物和方法
EA034733B1 (ru) * 2008-01-21 2020-03-13 Медикаго Инк. Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
WO2009128949A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
CA2742288A1 (en) * 2008-07-30 2010-02-04 Folia Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
JP2012525133A (ja) * 2009-05-01 2012-10-22 レッドバイオテック・アーゲー 多重遺伝子ベクターによってコードされる組換えウイルス様粒子
WO2010128100A1 (en) * 2009-05-08 2010-11-11 Glaxosmithkline Biologicals S.A. Method for producing virus from cell culture involving homogenization
PL222497B1 (pl) * 2009-06-26 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej
JP5886194B2 (ja) 2009-07-02 2016-03-16 マサチューセッツ インスティテュート オブ テクノロジー インフルエンザ感染の診断および／または処置のための組成物および方法
EP2483307A1 (en) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
WO2011046925A1 (en) * 2009-10-12 2011-04-21 Technovax, Inc. Respiratory syncytial virus (rsv) virus-like particles (vlps)
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
WO2011090731A1 (en) * 2009-12-28 2011-07-28 Martek Biosciences Corporation Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
WO2011090712A2 (en) * 2009-12-28 2011-07-28 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
CN102858368B (zh) 2010-02-18 2017-04-12 泰科诺瓦有限公司 通用病毒样颗粒(vlp)流感疫苗
CN102373182A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性囊病混合病毒样颗粒、制备方法和应用
CN102373183A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和新城疫混合病毒样颗粒、制备方法和应用
CN102370976B (zh) * 2010-08-09 2014-06-11 中山大学 猪流感病毒和猪口蹄疫病毒的混合病毒样颗粒、制备方法和应用
CN102373184A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性支气管炎混合病毒样颗粒、制备方法和应用
CN102373181B (zh) * 2010-08-09 2014-06-11 中山大学 猪流感病毒和猪蓝耳病病毒混合病毒样颗粒、制备方法和应用
US8802110B2 (en) 2010-09-21 2014-08-12 Massachusetts Institute Of Technology Influenza treatment and/or characterization, human-adapted HA polypeptides; vaccines
SG189236A1 (en) 2010-10-04 2013-05-31 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
BR112013032723A2 (pt) 2011-06-20 2017-01-31 Univ Pittsburgh Commonwealth Sys Higher Education antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
WO2013019800A1 (en) * 2011-08-01 2013-02-07 Emory University Vlps containing ligands and methods related thereto
ES2953393T3 (es) * 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
EP2827893B1 (en) 2012-03-22 2017-11-29 Fraunhofer USA, Inc. Virus-like particles comprising a matrix protein from a plant enveloped virus and uses thereof
AU2013240365B2 (en) 2012-03-30 2017-03-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H5N1 and H1N1 influenza viruses
TWI434933B (zh) * 2012-04-17 2014-04-21 Nat Univ Tsing Hua 抗多型禽流感病毒之ｄｎａ疫苗及其組合物
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CA2891682A1 (en) * 2012-11-27 2014-06-05 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h1n1 influenza
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
KR101729387B1 (ko) 2015-04-17 2017-04-21 경희대학교 산학협력단 곤충세포 발현시스템을 이용한 인플루엔자 백신 소재 ｍ1-ｍ2-ｎａ-ｈａ 바이러스 유사 입자의 제조방법
KR102758377B1 (ko) 2015-09-03 2025-01-23 노바백스, 인코포레이티드 개선된 안정성 및 면역원성을 갖는 백신 조성물
EP3347044B1 (en) * 2015-09-10 2023-04-19 Academia Sinica Bird flu vaccine combination comprising virus-like particles and novel adjuvants
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2018080889A1 (en) * 2016-10-31 2018-05-03 Georgia State University Research Foundation, Inc. A virus like particle of hepatitis b virus pre-s protein
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
MX2023012554A (es) 2018-12-12 2023-11-08 Cambridge Tech Llc Vacuna universal contra la gripe.
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
GB2601618B (en) 2019-03-19 2024-11-06 Broad Inst Inc Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
AU2021310950A1 (en) 2020-07-24 2023-02-16 President And Fellows Of Harvard College Enhanced virus-like particles and methods of use thereof for delivery to cells
CN116063409A (zh) * 2022-09-09 2023-05-05 中山大学·深圳 一种乙型流感Mosaic重组蛋白、重组质粒及其构建方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009258A (en) * 1972-09-25 1977-02-22 The Mount Sinai School Of Medicine Of The City University Of New York Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5298244A (en) * 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
US5830877A (en) * 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
WO2000018434A1 (en) 1998-09-30 2000-04-06 American Cyanamid Company Mutant cholera holotoxin as an adjuvant
AU4073300A (en) * 1999-04-06 2000-10-23 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
KR100877019B1 (ko) * 2000-06-23 2009-01-07 와이어쓰 홀딩스 코포레이션 야생형 및 키메릭 인플루엔자 바이러스성입자(브이엘피)의 조립

Also Published As

Publication number Publication date
JP2004501647A (ja) 2004-01-22
JP5008244B2 (ja) 2012-08-22
EP1294892A2 (en) 2003-03-26
KR100877019B1 (ko) 2009-01-07
MXPA02012254A (es) 2003-04-25
CN1196788C (zh) 2005-04-13
IL153290A0 (en) 2003-07-06
WO2002000885A9 (en) 2002-05-10
BR0111830B1 (pt) 2014-12-02
DE60130987T2 (de) 2008-07-24
BR0111830A (pt) 2003-03-25
CA2410297C (en) 2011-03-15
BRPI0111830B8 (pt) 2021-05-25
CY1107835T1 (el) 2013-06-19
CA2410297A1 (en) 2002-01-03
CN1437655A (zh) 2003-08-20
ES2295175T3 (es) 2008-04-16
WO2002000885A3 (en) 2002-08-08
DE60130987D1 (de) 2007-11-29
US20050186621A1 (en) 2005-08-25
AU2001268662A1 (en) 2002-01-08
US7556940B2 (en) 2009-07-07
KR20030013463A (ko) 2003-02-14
AU2007201727B2 (en) 2009-06-04
EP1294892B1 (en) 2007-10-17
PT1294892E (pt) 2008-01-16
WO2002000885A2 (en) 2002-01-03
AU2007201727A1 (en) 2007-05-10
US20090239261A1 (en) 2009-09-24
US8859231B2 (en) 2014-10-14
ATE376059T1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
DK1294892T3 (da) Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)
EA200401064A1 (ru) Вирусоподобные частицы из вируса папилломы человека
BR0113307A (pt) Molécula de proteìna quimérica de núcleo de vìrus de hepatite b recombinante, partìcula imunogênica, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, célula hospedeira e método de induzir uma resposta imunológica em um animal hospedeiro inoculado
DE69535018D1 (de) Papillomavirus vakzine
LU91390I2 (fr) "La combinaison de particules viroïdes de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - CERVARIX
ES2263406T1 (es) Produccion de proteina capsida l1 y particulas tipo virus de papilomavirus humano hbv-11.
WO2004042001A3 (en) Virus-like particles, methods of preparation, and immonogenic compositions
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
WO2005055957A3 (en) Influenza immunogen and vaccine
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
DK0677114T3 (da) Rekombinant svinekoppevirus
ATE352557T1 (de) Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff
WO2004004761A3 (en) Adjuvant viral particle
WO2002000169A3 (en) Production of vaccines using transgenic plants
CY1106310T1 (el) Καθορισμος hbv αντιγονων για χρηση σε εμβολια
DK1159968T3 (da) Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning
ATE418997T1 (de) Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
DE60330966D1 (de) Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
ATE408013T1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
RU2007113184A (ru) Оральная вакцина
DE69930960D1 (de) Synthetische virus-ähnliche partikel mit heterologen epitopen.
DE69728447D1 (de) Veränderte, kleine rna-viren
ATE489106T1 (de) Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen
WO2004104033A3 (en) Viruses dependent on inducing agents for viral entry into a host cell